Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BAP1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

BAP1 mutation	Mesothelioma	BAP1 mutation	Mesothelioma	olaparib Resistant: C2 – Inclusion Criteria olaparib Resistant : C2	olaparib Resistant: C2 – Inclusion Criteria olaparib Resistant : C2
BAP1 mutation	Mesothelioma	BAP1 mutation	Mesothelioma	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2
BAP1 mutation	Urothelial Cancer	BAP1 mutation	Urothelial Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
BAP1 mutation	Melanoma	BAP1 mutation	Melanoma	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2
BAP1 mutation	Cholangiocarcinoma	BAP1 mutation	Cholangiocarcinoma	cisplatin + gemcitabine Resistant: C3 – Early Trials cisplatin + gemcitabine Resistant : C3	cisplatin + gemcitabine Resistant: C3 – Early Trials cisplatin + gemcitabine Resistant : C3
BAP1 mutation	Renal Cell Carcinoma	BAP1 mutation	Renal Cell Carcinoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
BAP1 mutation	Renal Cell Carcinoma	BAP1 mutation	Renal Cell Carcinoma	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
BAP1 mutation	Mesothelioma	BAP1 mutation	Mesothelioma	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
BAP1 mutation	Cholangiocarcinoma	BAP1 mutation	Cholangiocarcinoma	FF-10502 Sensitive: C3 – Early Trials FF-10502 Sensitive : C3	FF-10502 Sensitive: C3 – Early Trials FF-10502 Sensitive : C3
BAP1 mutation	Clear Cell Renal Cell Carcinoma	BAP1 mutation	Clear Cell Renal Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
BAP1 mutation	Malignant Pleural Mesothelioma	BAP1 mutation	Malignant Pleural Mesothelioma	niraparib + dostarlimab-gxly Sensitive: C4 – Case Studies niraparib + dostarlimab-gxly Sensitive : C4	niraparib + dostarlimab-gxly Sensitive: C4 – Case Studies niraparib + dostarlimab-gxly Sensitive : C4
BAP1 mutation	Renal Cell Carcinoma	BAP1 mutation	Renal Cell Carcinoma	Glutamate inhibitor Sensitive: D – Preclinical Glutamate inhibitor Sensitive : D	Glutamate inhibitor Sensitive: D – Preclinical Glutamate inhibitor Sensitive : D
BAP1 mutation	Uveal Melanoma	BAP1 mutation	Uveal Melanoma	JNJ 26481585 Sensitive: D – Preclinical JNJ 26481585 Sensitive : D	JNJ 26481585 Sensitive: D – Preclinical JNJ 26481585 Sensitive : D
BAP1 mutation	Solid Tumor	BAP1 mutation	Solid Tumor	BET inhibitor Sensitive: D – Preclinical BET inhibitor Sensitive : D	BET inhibitor Sensitive: D – Preclinical BET inhibitor Sensitive : D